Mirati plots a march to the FDA for its KRAS G12C drug, breathing down Amgen’s neck with better data

Mirati Therapeutics $MRTX took another closely-watched step toward a now clearly defined goal to file for an approval for its KRAS G12C cancer drug adagrasib (MRTX849), scoring a higher response rate than the last readout from the class-leading rival at Amgen but still leaving open a raft of important questions…

Click to view original post